Clinical trials: Ejection Fraction
Cardiac Output, Low
Evaluation of the Impact of Ejection Fraction on Clinical Outcomes in Patients Undergoing Cardiovascular Surgery
This study evaluates the impact of ejection fraction (EF) on clinical outcomes in patients undergoing cardiovascular surgeries, specifically coronary artery bypass grafting (CABG) and heart valve replacement.
- Trial name
- NCT06468657
- Testing
- mortality rates
- Where
- Turkey (Türkiye)
- Volunteers
- 610 people
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
Chronic Heart Failure
Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure
This was a multicenter, randomized, double-blind, crossover, placebo-controlled, Phase II clinical study that evaluated the effect of serelaxin versus placebo (both in addition to SoC) on the release of hs-cTnI, in patients with…
- Trial name
- RELAX-Cardio (NCT02625922)
- Testing
- Serelaxin
- Where
- 9 sites in Germany, Switzerland and 1 more
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
Pilot Study on Withdrawal of Spironolactone Among Heart Failure With Improved Ejection Fraction
The study is a randomized controlled pilot trial to evaluate whether withdrawal of spironolactone is safe and associated with re-deterioration of left ventricular function in patients with heart failure with improved ejection…
- Trial name
- NCT04367051
- Testing
- Withdrawal of Spironolactone, Continuation of spironolactone
- Where
- South Korea
- Volunteers
- 62 people
- Sponsor
- Asan Medical Center
Healthy
Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying
This is a clinical research study to establish normal values for the infusion of a synthetic form of the hormone cholecystokinin(CCK-8) for gallbladder emptying.
- Trial name
- NCT00685477
- Testing
- Experimental Sequence ABC, Experimental Sequence ACB, Experimental Sequence BAC
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Temple University
Heart Failure, Systolic, Ketonemia
Ketones in Heart Failure - Effects on Cardiac Efficiency
Ketones may have beneficial effects on myocardial metabolism and hemodynamics. In the present study, healthy test subjects and patients with heart failure with reduced ejections fraction will be investigated in a randomized…
- Trial name
- NCT03073356
- Testing
- Infusion of 3-OHB
- Where
- Denmark
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Heart Failure, Worsening Heart Failure
Metabolic Changes in Heart Failure Patients Treated With Vericiguat
Heart failure is a condition in which the heart cannot pump blood as effectively as it should. It can cause symptoms such as shortness of breath, tiredness, and fluid retention.
- Conditions
- Heart Failure, Worsening Heart Failure, Heart Failure With Reduced Ejection Fraction
- Trial name
- VERI-MET (NCT07901270)
- Testing
- Vericiguat
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Salerno
Heart Failure With Preserved Ejection Fraction (HFPEF)
This Will be a Randomized Comparison of the Proteomic Effects of Vicadrostat/Empagliflozin Versus Empagliflozin and Versus Empagliflozin/Spironolactone in Heart Failure Patients With Preserved Ejection Fraction
The SPECTRA-HFpEF Study is a randomized, double-blind, Phase 2 clinical study designed to evaluate and compare the biological effects of vicadrostat in combination with empagliflozin, empagliflozin alone, and spironolactone in…
- Trial name
- SPECTRA-HFpEF (NCT07857772)
- Testing
- empa plus vica, Comparator: empa 10 plus spironolactone
- Volunteers
- 200 people
- Sponsor
- Baim Institute for Clinical Research
Heart Failure With Preserved Ejection Fraction
Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction
To determine biomarker responses to Entresto™in patients with Heart Failure with preserved Ejection Fraction (HFpEF) and who have high or low serum neprilysin (NEP) levels.
- Trial name
- CNEPi (NCT03506412)
- Testing
- Entresto™ 49Mg-51 mg tablet
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Mayo Clinic
Heart Failure
Digoxin Versus Ivabradine in Heart Failure With Reduced Ejection Fraction
Study hypothesis: Comparing the effect of digoxin and ivabradine in chronic heart failure patients with a left ventricular ejection of 35% or lower and sinus rhythm with heart rate 70 beats per minute or higher, and who are…
- Trial name
- DIVA-REF (NCT02046044)
- Testing
- Digoxin, Ivabradine
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Kocaeli University
Chronic Obstructive Pulmonary Disease, Heart Failure
HFpEF and 2-year Mortality of COPD Patients
This study was designed to assess potential relationship between heart failure with preserved ejection fraction and 2- year mortality of patients with chronic obstructive pulmonary disease
- Trial name
- THERESE (NCT04277429)
- Testing
- Cardiac function assessment
- Where
- 2 sites in Czechia
- Volunteers
- 150 people
- Sponsor
- University Hospital Olomouc
Valvular Heart Disease Stenosis and Regurgitation
Different Methods of Cardiac MRI in Assessment of Estimated Corrected Ejection Fraction in Valvular Heart Diseases
Comparative study between Phase Contrast , Modified Simpson Rule and Myocardial Strain Analysis methods of Cardiac Magnetic Resonance Imaging in assessment of Corrected Estimated Ejection Fraction in Valvular Heart Disease To…
- Trial name
- NCT05808465
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Assiut University
Non-ischemic Cardiomyopathy, Dilated Cardiomyopathy (DCM)
Multimodal and Multidisciplinary Approach to Optimize Diagnostic, Prognostic, and Therapeutic Management of Patients with Non-ischemic Cardiomyopathies and Arrhythmogenic-inflammatory Phenotypes: a Multicenter, Observational, Retrospective and Prospective Registry Study.
Non-ischemic cardiomyopathies (NICM) represent a heterogeneous group of pathologies characterized by absence of obstructive disease of the epicardial coronary vessels and distinct structural and functional changes of the…
- Conditions
- Non-ischemic Cardiomyopathy, Dilated Cardiomyopathy (DCM), Hypertrophic Cardiomyopathy (HCM), Restrictive Cardiomyopathy
- Trial name
- AINICM (NCT06607471)
- Testing
- Support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation, Support treatment, cardiac medical treatment, aetiology-specific treatment
- Where
- Italy
- Volunteers
- 15,000 people
- Sponsor
- Scientific Institute San Raffaele
HFrEF - Heart Failure With Reduced Ejection Fraction, Cardiac Rehabilitation
Predictive Factors of Response to Phase II Cardiac Rehabilitation in Heart Failure With Reduced Ejection Fraction
Exercise intolerance, measured as peak oxygen consumption (VO₂peak) during exercise in patients with heart failure with reduced ejection fraction (HFrEF).
- Conditions
- HFrEF - Heart Failure With Reduced Ejection Fraction, Cardiac Rehabilitation, Exercise Training, Exercise Adaptations
- Trial name
- PrédicRéa (NCT07164911)
- Where
- France
- Volunteers
- 62 people
- Sponsor
- Centre Hospitalier de Corbie
Heart Failure, Preserved Ejection Fraction
Randomized Double-blind Controlled Clinical Study of SGLT-2i Combined With Probiotic Preparations in Elderly Patients With HFpEF
HFpEF has a high incidence and lacks effective therapy, and its onset is closely related to systemic inflammation and intestinal dysbacteriosis.SGLT-2i exerts its effects by diuresis, anti-inflammatory and improving energy…
- Trial name
- NCT07687212
- Testing
- Henggliflozin Combined with Probiotics, Henggliflozin
- Where
- China
- Volunteers
- 162 people
- Sponsor
- The First Affiliated Hospital of Air Force Medical University
Heart Failure, Heart Failure With Preserved Ejection Fraction
Assessment of CCM in HF With Higher Ejection Fraction
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.
- Conditions
- Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction
- Trial name
- AIM HIGHer (NCT05064709)
- Testing
- Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, OPTIMIZER™ Smart Mini System
- Where
- 67 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Impulse Dynamics
Heart Failure, Obstructive Sleep Apnea
Sleep Apnea in Heart Failure With Preserved Ejection Fraction
This is a prospective interventional study to better understand i) the prevalence of Obstructive Sleep Apnea (OSA) in Heart Failure with preserved Ejection Fraction (HFpEF), ii) its hemodynamic correlates, and iii) the impact of…
- Trial name
- NCT05008432
- Testing
- Home sleep apnea testing
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Mayo Clinic
Heart Failure With Preserved Ejection Fraction
Optimising Management of Patients With Heart Failure With Preserved Ejection Fraction in Primary Care
Heart failure (HF) accounts for 2% of National Health Service (NHS) expenditure, and 5% of emergency hospitalisations. Patients with HF with preserved ejection fraction (HFpEF) are older, have more comorbidities, have similarly…
- Trial name
- OPTIMISEHFpEF (NCT03617848)
- Where
- United Kingdom
- Volunteers
- 153 people
- Sponsor
- Professor Christi Deaton
Heart Failure With Preserved Ejection Fraction, Diabetes Mellitus, Type 2
Modulation of Circulating Levels of the Ketone Body 3-hydroxybutyrate in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction: Cardiovascular Effects.
Heart failure (HF) is among the most common causes of death in patients with type 2 diabetes (T2D). Ketones, 3-hydroxybutyrate (3-OHB), have shown to have beneficial hemodynamics effect in patients with hearth failure with…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Diabetes Mellitus, Type 2, Ketonemia
- Trial name
- KETO-HFpEF (NCT05236335)
- Testing
- Ketone ester
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- University of Aarhus
Heart Failure with Preserved Ejection Fraction
HFPEF-project: Heart Failure Phenotyping - Exploring the Fingerprints
With an ageing population, the number of patients with heart failure with preserved ejection fraction (HFpEF) or diastolic heart failure is increasing rapidly.
- Trial name
- NCT06465043
- Where
- Finland
- Volunteers
- 300 people
- Sponsor
- University of Helsinki
Heart Failure With Preserved Ejection Fraction, Prognathism
Effect of Bilirubin on Prognosis in Heart Failure With Preserved Ejection Fraction
Factors influencing the prognosis of patients with heart failure with preserved ejection fraction (HFpEF) have been extensively studied.
- Trial name
- NCT06379152
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Chongqing Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.